» Articles » PMID: 20853547

Global Programme to Eliminate Lymphatic Filariasis

Overview
Date 2010 Sep 22
PMID 20853547
Citations 20
Affiliations
Soon will be listed here.
Citing Articles

Integrating post-validation surveillance of lymphatic filariasis with the WHO STEPwise approach to non-communicable disease risk factor surveillance in Niue, a study protocol.

Craig A, Lawford H, Mokoia G, Ikimau M, Fetaui P, Marqardt T PLoS One. 2025; 20(1):e0315625.

PMID: 39820223 PMC: 11737670. DOI: 10.1371/journal.pone.0315625.


Perspectives on the implementation of post-validation surveillance for lymphatic filariasis in the Pacific Islands: A nominal group technique-based study protocol.

Craig A, Lawford H, Viali S, Tuitama G, Lau C PLoS One. 2024; 19(12):e0313957.

PMID: 39621605 PMC: 11611168. DOI: 10.1371/journal.pone.0313957.


Operational research to inform post-validation surveillance of lymphatic filariasis in Tonga study protocol: History of lymphatic filariasis elimination, rational, objectives, and design.

Lawford H, Tukia O, Takai J, Sheridan S, Lau C PLoS One. 2024; 19(8):e0307331.

PMID: 39163407 PMC: 11335152. DOI: 10.1371/journal.pone.0307331.


Anti-filarial antibodies are sensitive indicators of lymphatic filariasis transmission and enable identification of high-risk populations and hotspots.

Lawford H, Mayfield H, Sam F, Viali S, Kamu T, Cooley G Int J Infect Dis. 2024; 147:107194.

PMID: 39074737 PMC: 11530377. DOI: 10.1016/j.ijid.2024.107194.


Repurposed Drugs That Activate Autophagy in Filarial Worms Act as Effective Macrofilaricides.

Voronin D, Tricoche N, Peguero R, Kaminska A, Ghedin E, Sakanari J Pharmaceutics. 2024; 16(2).

PMID: 38399310 PMC: 10891619. DOI: 10.3390/pharmaceutics16020256.